Vimarsana
Biggest News Aggregation in the World

Colitis Organisation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Colitis Organisation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Colitis Organisation Today - Breaking & Trending Today

AbbVie Reports First-Quarter 2024 Financial Results - Vimarsana News

AbbVie Reports First-Quarter 2024 Financial Results

Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These...

Mindfulness-Based Cognitive Therapy Reduces IBD-Related Psychological Distress - Vimarsana News

Mindfulness-Based Cognitive Therapy Reduces IBD-Related Psychological Distress

Mindfulness-based cognitive therapy decreases psychological distress and improves positive mental health and fatigue in adults with IBD.

AI-Identified Vascular Healing Can Predict Relapse in UC - Vimarsana News

AI-Identified Vascular Healing Can Predict Relapse in UC

An AI-assisted image-enhanced endoscopy system accurately assessed vascular healing and predicted clinical relapse in patients with ulcerative colitis.

Capsule Endoscopy–Guided Treatment Reduces Flares in Crohn's - Vimarsana News

Capsule Endoscopy–Guided Treatment Reduces Flares in Crohn's

Patients with Crohn's disease who are considered high-risk as determined by capsule endoscopy but are in clinical remission benefit from a treat-to-target strategy, a new study shows.

Celltrion presents new twoyear data for subcutaneous infliximab CTP13 SC in inflammatory bowel disease IBD at the 19th ECCO Congress - Vimarsana News

Celltrion presents new twoyear data for subcutaneous infliximab CTP13 SC in inflammatory bowel disease IBD at the 19th ECCO Congress

Celltrion today presented positive twoyear results from the extended LIBERTY studies LIBERTYCD1 and LIBERTYUC2 in patients with moderately to severely active Crohns disease CD and ulcerative colitis UC. Celltrion also presented endoscopic outcomes from the posthoc analysis of the LIBERTYCD study.3